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ABSTRACT
Hiccups are involuntary, spasmodic contractions of the diaphragm and intercostal 
muscles and can be classified as acute (< 48 h), persistent (48 h to a month) or intractable 
(> 1 month). A previously healthy 29-year-old man sought the Emergency Department with 
flu-like symptoms and a two-day history of persistent hiccups. His physical examination was 
otherwise unremarkable and vital signs were within normal limits. An unenhanced computed 
tomography scan of the chest showed small focal ground-glass opacities scattered throughout 
25% of the lungs. A COVID-19 test was positive. Chlorpromazine was prescribed for the 
hiccups with improvement over 10 h. The patient was discharged home on the same day 
without hiccups and no other complications. 
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INTRODUCTION
Hiccups are diaphragmatic and intercostal muscle contractions with early glottis 
closure terminating the inspiration. They are involuntary and spasmodic, and are 
controlled by a complex reflex arc between peripheral receptors and the brainstem. 
Any disruption along this pathway may produce hiccups. Hiccups can be classified 
as acute (< 48 h), persistent (48 h to a month) or intractable (> 1 month). Most acute 
hiccups are transient, benign and self-limited. However, persistent and intractable 
hiccups may be considered a sign of underlying pathology and although the most 
common cause is gastroesophageal reflux disease (GERD), atypical causes as 
COVID-19 are now identified in rare reports in the literature1,2.
CASE REPORT
A 29-year old man sought the Emergency Department complaining of hiccups 
in the last 2 days. The patient reported one febrile episode of 37.8 oC which 
improved after the use of acetaminophen, and a 3-day history of cough, rhinorrhea 
and mild shortness of breathe. Upon admission, he denied feeling tightness in his 
chest or a sore throat. The patient had no previous history of chronic diseases or 
allergies and denied abuse of alcohol, other drugs and was not a smoker. His blood 
pressure was 132/74 cmHg, the respiratory rate was 20 breaths/min, his heart rate 
was 73 beats/min and regular, the body temperature was 36.4 oC and the oxygen 
saturation was 94% in room air. There were bilateral scattered crackles during 
the auscultation of the lungs and no signs of respiratory insufficiency. The head 
and the neurological examination were normal. Routine blood test results were as 
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follows: red blood cells 4.74 x 106 cells/uL; white blood 
cells 7.75 x 103 cells/uL; neutrophils 81.2%; lymphocytes 
13.4%; total number of lymphocytes 1.039 x 103 cells/uL; 
platelets 194 x 103 cells/uL; C-reactive protein (CRP) 
32 mg/L; potassium4.2 mEq/L; sodium137 mEq/L; BUN 
15.4 mg/dL; serum creatinine (Cr) 1.04 mg/dL; D-dimer 
142 ng/mL; lactate dehydrogenase (LDH) 179 U/L; 
ferritin 245 ng/mL; troponin 1.4 pg/mL. His arterial blood 
gas analysis was as follows: pH 7.41; pCO
2
 36 mmHg; 
pO
2
 83 mmHg; Oxygen saturation 96%; HCO
3
 22.8 mEq/L; 
Base excess -2.1 mEq/L.
The chest computed tomography (CT) was performed 
and small subpleural ground-glass opacities, as well as 
small sparse areas of atelectasis were observed scattered 
across the two lungs and affecting less than 25% of lung 
parenchyma, suggesting the presence of a viral pneumonia 
(Figure 1). A real-time reverse transcription-polymerase 
chain reaction (RT-PCR) analysis of the patient’s throat 
swab sample confirmed the SARS-Cov-2 infection. 
The Valsalva maneuver used in an attempt to stop the 
hiccups was unsuccessful. As the patient did not meet 
the Centers for Disease Control and Prevention (CDC) 
established criteria for COVID-19 severe illness, he 
was discharged home with symptomatic medication3. 
The patient was followed-up by phone for 10 days and 
treated with chlorpromazine for the resistant hiccups, 
which disappeared 10 h after starting treatment. The 
chlorpromazine treatment was continued for three days, 
for a total of five days, and there was no relapse after 
treatment discontinuation. 
DISCUSSION
Since the first COVID-19 report, clinical manifestations 
were described in most cases as fever, nonproductive cough, 
dyspnea, myalgia, fatigue, normal or decreased leukocyte 
count, in addition to radiographic evidence of pneumonia 
in the chest CT scan.
The severe presentation of COVID-19 included 
organ dysfunction, clinically presenting as shock, acute 
respiratory distress syndrome (ARDS), acute cardiac injury, 
acute kidney injury and death4. However, with the growing 
COVID-19 data around the world, different presentations 
have been reported, highlighting the clinical heterogeneity 
of this disease. This case reports a patient with an atypical 
presentation: persistent hiccups5.
The correlation between COVID-19 and hiccups still 
remains unclear, but other infectious conditions such as 
influenza, herpes zoster, neurosyphilis and tuberculosis 
have been related to hiccups6,7. 
The severity and treatment of hiccups depend on their 
temporal classification. Acute hiccups are usually benign 
and self-limited, not requiring intervention or etiological 
investigation in the majority of cases. However, patients 
whose hiccups interfere with their quality of life may 
attempt physical maneuvers to relieve their symptoms. 
These maneuvers are harmless to the patient and they work 
by increasing the vagal stimulus, interrupting the normal 
respiratory rhythm an the nasopharynx stimulus. There 
are several methods: breath holding, Valsalva’s maneuver, 
eyeball compression, drinking cold water, pulling out the 
tongue, among others6,8.
Persistent hiccups usually interfere with the patient’s 
daily activities and they often hide a pathological etiology, 
therefore the underlying cause should be investigated. 
Some common causes are gastroesophageal reflux (GERD), 
malignancies, myocardial infarction, cerebrovascular 
diseases, medications, toxic metabolites, infectious 
agents, among others. Physical maneuvers may be initially 
attempted in order to relieve the symptoms, but in contrast 
to acute hiccups, persistent and intractable hiccups are less 
likely to be terminated by physical therapy.
The treatment should always be focused on the 
underlying cause, but an empiric treatment can be used 
while the etiology is under investigation. The first empiric 
option should be a proton pump inhibitor, as the most 
common cause of persistent hiccups is GERD. In the 
absence of symptoms improvement or the diagnosis of 
a serious etiology, a wide variety of medications can be 
used. The most common options are baclofen, gabapentin, 
metoclopramide and chlorpromazine6. In our case, 
chlorpromazine was used as the first option due to the drug 
availability. Similar case reports of COVID-19 associated 
with hiccups are presented in Table 1. Briefly, including 
the case reported here, there are 10 cases of COVID-19 
(confirmed by RT-PCR) associated with hiccups in the 
literature, all of them in male patients aged 29-68 years, 
Figure 1 - A chest computed tomography scan showing 
peripheral ground-glass opacities in lungs.
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with abnormal chest CT scan or chest X-rays of the lungs, 
all patients but one received medications to stop the hiccups, 
and according to the follow-up description, eight patients 
evolved with improvement of symptoms, including ours, 
one case was lost to follow-up, and in one case data were 
not available in the medical record. 
CONCLUSION 
During the COVID-19 pandemic, health care workers 
must maintain a high clinical suspicion of COVID-19 
examining patients with atypical presentations of this 
disease, such as persistent hiccups.
Table 1 - Similar case reports of COVID-19 associated with hiccups.
Gender and age 
of the patient 
(years)






Chest CT scan with ground-
glass opacities and small 
sparse areas of atelectasis 










Chest CT scan with ground-
glass in the left lower lobe 












Chest CT scan with ground-
glass in the left lower lobe 








Chest CT scan with ground-
glass in the left lower lobe 











Chest CT scan with ground-
glass opacities 









Chest CT scan with ground-
glass opacities 










Chest CT scan with ground-
glass opacities 


















Chest X-ray showing lung 
parenchyma with decreased 
radiolucency of images with 











Chest X-ray with bilateral lower 
lobe infiltrates 










Chest X-ray with bilateral 
middle lung opacities 









Chest CT scan with viral 
pneumonia 






RT-PCR = real-time reverse transcription-polymerase chain reaction
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